Ironwood Pharmaceuticals | IRWD - Assets


Ironwood Pharmaceuticals reported $434.57M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
Almirall EUR 2.34B 29.21M Dec/2025
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amarin USD 645.76M 25.01M Mar/2026
Ardelyx USD 504.51M 2.9M Mar/2026
Astellas Pharma JPY 3.57T 36.87B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Charles River Laboratories USD 7.73B 594.89M Mar/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Moderna USD 11.49B 850M Mar/2026
Myriad Genetics USD 673.7M 32.9M Mar/2026
Pacira USD 1.21B 56.38M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Takeda JPY 15.45T 44.34B Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025